5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderRecruitingPhase 22026-10-08NCT06226883
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsHemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndromeRecruitingPhase 32026-09-18NCT07422480
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasB-cell neoplasm, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, T-cell non-Hodgkin lymphoma, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenoma, diffuse large B-cell lymphoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorderRecruitingPhase 1 / Phase 22026-08-19NCT04104776
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsNeoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumorActive, not recruitingPhase 32026-08-07NCT03049189
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibHemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosisRecruitingPhase 32025-09-25NCT06479135